ZZM-1220
Product Specifications
UNSPSC Description
ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase[1].
Target Antigen
Apoptosis; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis;Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zzm-1220.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(C2=NC3=CC(OC)=C(C=C3C(NC4CCN(CC4)C)=N2)OC)=CC=C1)=O
Molecular Weight
447.53
References & Citations
[1]Qiangsheng Zhang, et al. Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2023 Sep 28:261:115841.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-156285/ZZM-1220-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-156285/ZZM-1220-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
V9326-20UG 20 µg
CFTR Recombinant Antibody / Cystic Fibrosis Transmembrane Regulator
Ask
View Details